Advertisement
| colorectal cancer targeted therapy: Colon Cancer Diagnosis and Therapy Ganji Purnachandra Nagaraju, Dhananjay Shukla, Naveen Kumar Vishvakarma, 2021-06-10 Colorectal cancer (CRC) is a major global health challenge as the third leading cause for cancer related mortalities worldwide. Despite advances in therapeutic strategies, the five-year survival rate for CRC patients has remained the same over time due to the fact that patients are often diagnosed in advanced metastatic stages. Drug resistance is another common reason for poor prognosis. Researchers are now developing advanced therapeutic strategies such as immunotherapy, targeted therapy, and combination nanotechnology for drug delivery. In addition, the identification of new biomarkers will potentiate early stage diagnosis. This book is the first of three volumes on recent developments in colorectal diagnosis and therapy. Each volume can be read on its own, or together. Each volume focuses on different novel therapeutic advances, biomarkers, and identifies therapeutic targets for treatment. Written by leading international experts in the field, coverage also addresses the role of diet habits and lifestyle in reducing gastrointestinal disorders and incidence of CRC. Chapters discuss current and future diagnostic and therapeutic options for colorectal cancer patients, focusing on immunotherapeutic, nanomedicine, biomarkers, and dietary factors for the effective management of colon cancer. |
| colorectal cancer targeted therapy: Colon Cancer Diagnosis and Therapy Naveen Kumar Vishvakarma, Ganji Purnachandra Nagaraju, Dhananjay Shukla, 2021-06-04 Colorectal cancer (CRC) is a major global health challenge as the third leading cause for cancer related mortalities worldwide. Despite advances in therapeutic strategies, the five-year survival rate for CRC patients has remained the same over time due to the fact that patients are often diagnosed in advanced metastatic stages. Drug resistance is another common reason for poor prognosis. Researchers are now developing advanced therapeutic strategies such as immunotherapy, targeted therapy, and combination nanotechnology for drug delivery. In addition, the identification of new biomarkers will potentiate early stage diagnosis. This book is the second of three volumes on recent developments in colorectal diagnosis and therapy. Each volume can be read on its own, or together. Each volume focuses on different novel therapeutic advances, biomarkers, and identifies therapeutic targets for treatment. Written by leading international experts in the field, coverage addresses the role of diet habits and lifestyle in reducing gastrointestinal disorders and incidence of CRC. Chapters discuss current and future diagnostic and therapeutic options for colorectal cancer patients, focusing on immunotherapeutics, nanomedicine, biomarkers, and dietary factors for the effective management of colon cancer. |
| colorectal cancer targeted therapy: Targeted Therapy of Colorectal Cancer Subtypes Peter Jordan, 2019-01-08 Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide. Recent years have increased significantly our understanding of the genetic alterations that can underlie CRC, but also unraveled the molecular heterogeneity of the disease. Although a simple correlation between genetic pathways, histopathological features and clinical outcome cannot be established, the heterogeneity of CRC is also an opportunity for the development of targeted therapeutic approaches, able to treat an individual tumor with higher efficiency and less toxic side effects. One CRC subtype is characterized by high mutation rates (MSI-H), DNA methylation changes (CIMP-H), mutation in the BRAF oncogene and occurrence of serrated adenomas in the proximal colon. Other groups prevail in the distal colon and consist of either adenomatous polyps with chromosomal aberrations (CIN) and WNT pathway activation, or carry frequent KRAS mutation and metabolic deregulation, or have strong mesenchymal and infiltrative characteristics. Characterization of driver-mutation events in these CRC subgroups has led to the development of specific drugs targeting, for example, the MAPK pathway, but initial clinical trials have revealed unexpected response rates. The collection of chapters in this volume address the biology of specific CRC subtypes and how these may be targeted to improve precision therapy and clinical benefit for the patients. |
| colorectal cancer targeted therapy: Rectal Cancer Treatment M.W. Büchler, R. J. Heald, B. Ulrich, J. Weitz, 2005-10-11 Rectal cancer is one of the most prevalent cancers world-wide. It is also a paradigm for multimodal management, as the combination of surgery, chemotherapy and radiotherapy is often necessary to achieve the optimal outcome. Recently, international experts met in Heidelberg, Germany to discuss the latest developments in the management of rectal cancer, including the anatomic and pathologic basis, staging tools, surgical concepts including fast-track surgery and laparoscopic resection, functional outcome after surgery and the role of radio- and chemotherapy. This monograph summarizes this meeting and gives an extensive overview of the current concepts in management of rectal cancer. |
| colorectal cancer targeted therapy: Colorectal Cancer Valeria Barresi, 2022 Colorectal cancer is one of the most common malignancies worldwide, and the pathogenesis of this neoplasm is probably one of the most studied. The knowledge obtained over time has led to the development of screening and early diagnosis systems, allowing a significant reduction in the incidence of this neoplasm. However, what is currently known probably represents only the tip of the iceberg of the biology of this tumor. It was recently shown that the gut microbiota may contribute to colorectal cancerogenesis. In addition, several novel targeted therapies are now applied to patients with colorectal carcinoma. Nonetheless, several questions are still unanswered. Could the modulation of the gut microbiota modify the risk of tumor progression or the efficacy of therapies? Are there any predictive biomarkers of the risk of tumor progression or the efficacy of target therapies? Is metastatic colorectal cancer one or more diseases? This book collects a series of scientific articles reflecting part of the state of the art regarding colorectal cancer, seeking to answer these questions. |
| colorectal cancer targeted therapy: Current Medical Treatment Cyril William Holmes Havard, 1976 |
| colorectal cancer targeted therapy: Targeted Radionuclide Therapy Tod W. Speer, 2012-03-28 Radioimmunotherapy, also known as systemic targeted radiation therapy, uses antibodies, antibody fragments, or compounds as carriers to guide radiation to the targets. It is a topic rapidly increasing in importance and success in treatment of cancer patients. This book represents a comprehensive amalgamation of the radiation physics, chemistry, radiobiology, tumor models, and clinical data for targeted radionuclide therapy. It outlines the current challenges and provides a glimpse at future directions. With significant advances in cell biology and molecular engineering, many targeting constructs are now available that will safely deliver these highly cytotoxic radionuclides in a targeted fashion. A companion website includes the full text and an image bank. |
| colorectal cancer targeted therapy: Advances in Cancer Treatment Iago Dillion Lima Cavalcanti, José Cleberson Santos Soares, 2021-02-24 This work covers the pathophysiology of cancer, exploring the difficulty of optimal treatment due to the complexity and diversity of cancer types. The search for distinctive molecular biology characteristics of tumor cells is especially relevant in the identification of overexpressed receptors and proteins that can be used as a target for cancer treatment. We highlight the main therapeutic modalities, particularly conventional systemic chemotherapy, addressing its mechanisms of action, therapeutic classes and even the toxic effects. We also describe the main tumor markers, their importance in the diagnosis and treatment of cancer, and the specificity of tumor cells. The first chapters serve as an introduction to the central topic of this book, targeted therapy. Key aspects of target therapy, such as classes of drugs, immunotherapy, monoclonal antibodies, checkpoint inhibitors, cancer vaccines and tyrosine kinase inhibitors are presented, and, for each one, the benefits, as well as the adverse effects are reported. Chapter 6 compares conventional systemic chemotherapy and targeted therapy, identifies the risks and benefits and also the eligibility criteria for patient care. The possibility of targeted therapy replacing conventional chemotherapy is discussed while reviewing studies that demonstrate the benefits of combining both types of treatment. Finally, the introduction of pharmaceutical nanotechnology to improve antineoplastic agents is addressed in the last chapter and sets the direction for future research in cancer treatment. This is a valuable resource for many health professionals including physicians, pharmacists, nurses, researchers and students interested in the field of oncology. |
| colorectal cancer targeted therapy: Targeted Therapies in Breast Cancer Gw Sledge, George W. Sledge (Jr.), 2012-06 This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management. |
| colorectal cancer targeted therapy: Colorectal Cancer Liver Metastases Mauro Monteiro Correia, Michael A. Choti, Flavio G. Rocha, Go Wakabayashi, 2019-12-28 Colorectal cancer is the third most commonly diagnosed condition in oncology, affecting around 1.23 million individuals per year, according to recent statistics. Of these patients, about 50% will develop liver metastases and approximately 20% will present a stage IV disease at diagnosis. These statistics make colorectal liver metastases (CLM) an issue of major importance in current oncology. The area of CLM is subject to great and continuous advances, as its pathophysiologic mechanisms are better understood and more therapeutic and surgical options are developed. Consequently, all professionals involved with the diagnosis, treatment and follow up of CLM should be kept up to date with the latest advances on the field, to provide high standard medical care to their patients. This book is designed to present the state-of-the-art in CLM management and, in doing so, to review the current evidence on CLM, discussing all important topics in the field. Coverage is broad and comprehensive, encompassing introductory topics (history, definitions, epidemiology, etc.), basic science subjects (molecular biology, genetics, dissemination process, etc.) and practical clinical topics (tumor behavior, diagnosis, drug therapy, radiation therapy, surgery, ablation, multidisciplinary teams, etc.). Although comprehensive on the coverage and selection of topics, each chapter is concise and objective, dissecting topics in a practical and direct format. Evidences and recommendations are included. Chapters display a brief introduction of the common knowledge, go straight to the detailed revision of the most recent years of the literature, and end with practical closing observations. This book is a tool for professionals (general and cancer surgeons, HPB surgeons, clinical oncologists, gastroenterologists and medical residents) and interns who search for a qualified and reader friendly revision on topics concerning Colorectal Cancer Liver Metastases. |
| colorectal cancer targeted therapy: Introduction to Basics of Pharmacology and Toxicology Abialbon Paul, Nishanthi Anandabaskar, Jayanthi Mathaiyan, Gerard Marshall Raj, 2021-03-13 This book explains the pharmacological relationships between the various systems in the human body. It offers a comprehensive overview of the pharmacology concerning the autonomic, central, and peripheral nervous systems. Presenting up-to-date information on chemical mediators and their significance, it highlights the therapeutic aspects of several diseases affecting the cardiovascular, renal, respiratory, gastrointestinal, endocrinal, and hematopoietic systems. The book also includes drug therapy for microbial and neoplastic diseases. It also comprises sections on immunopharmacology, dermatological, and ocular pharmacology providing valuable insights into these emerging and recent topics. Covering the diverse groups of drugs acting on different systems, the book reviews their actions, clinical uses, adverse effects, interactions, and subcellular mechanisms of action. It is divided into 11 parts, subdivided into several chapters that evaluate the basic pharmacological principles that govern the different types of body systems. This book is intended for academicians, researchers, and clinicians in industry and academic institutions in pharmaceutical, pharmacological sciences, pharmacy, medical sciences, physiology, neurosciences, biochemistry, molecular biology and other allied health sciences. |
| colorectal cancer targeted therapy: Gastrointestinal Malignancies Suzanne Russo, Sarah Hoffe, Edward Kim, 2017-12-30 This book is a practical guide on how best to incorporate advanced radiation therapy techniques into the multimodality treatment of a wide range of gastrointestinal tumors, including esophageal cancer, gastric cancer, hepatobiliary malignancies (primary and metastatic liver tumors, intrahepatic, perihilar, and extrahepatic cholangiocarcinomas, and gallbladder cancer), pancreatic cancer, colorectal cancer, and carcinoma of the anal canal. Practical considerations when treating patients with external beam radiation therapy, intensity-modulated radiation therapy, particle therapy, and stereotactic body radiation therapy are clearly explained. Detailed attention is devoted to the safety and efficacy of radiotherapy in combination with current and emerging systemic therapies (chemotherapy, immunotherapy, and biologic agents), surgery, and ablative therapy, and the advantages and disadvantages of alternative treatment approaches for different tumor types are carefully evaluated. The book will benefit radiation oncologists, medical and surgical oncologists, medical physicists, medical dosimetrists, and other oncology professionals. |
| colorectal cancer targeted therapy: Regional Chemotherapy Maurie Markman, 2000-01-02 Maurie Markman and a panel of distinguished clinicians and leading clinical investigators comprehensively review the current status of regional antineoplastic drug delivery in the management of malignant disease. These authorities present a critical analysis of both the rationale and limitations of regional therapy and discuss potential clinical trials designed to explain the effectiveness of this method of therapy in special settings. Their presentations describe many exciting and innovative strategies for using regional drug delivery in anticancer therapy, including coverage of such areas of special interest as colorectal, skin, lung, pancreatic, ovarian, and gastrointestinal cancers. Comprehensive and authoritative, Regional Chemotherapy: Clinical Research and Practice offers surgical and medical oncologists and clinical cancer investigators a gold-standard review of the current role and future development of this increasingly powerful weapon in the battle against cancer. |
| colorectal cancer targeted therapy: Targeted Therapies in Oncology, Second Edition Giuseppe Giaccone, Jean-Charles Soria, 2013-10-21 Since the last edition of this book, major advances have been made in our understanding of key pathways that control tumor progression. This has led to the development of new anticancer agents that have the ability to block the activity of proteins involved in neoplastic cell development and proliferation. Targeted Therapies in Oncology, Second Edition provides a concise timely panorama of existing targeted therapies and progress into future anticancer treatments. These therapies notably include: Targeted agents of immune checkpoints Signal-transduction inhibitors Antiangiogenic agents Vascular-disrupting agents Apoptosis modulators Stem cell inhibitors Tumor profiling for drug development The book emphasizes the biology behind this new class of drugs as well as the clinical achievements obtained. The contributors to this volume stand at the cutting edge of cancer research and treatment around the world. |
| colorectal cancer targeted therapy: Molecular Testing in Cancer George M. Yousef, Serge Jothy, 2014-04-21 Molecular Testing in Cancer provides a state of the art review of clinically relevant molecular pathology in cancer. The book provides a brief, easy to read review of commonly employed diagnostic molecular techniques including recently developed next generation analytic tools, and offers a system-based run-through of the utility of molecular testing in individual cancer types, as well as reviewing current markers in cancer diagnosis, prognosis, and management. The volume also provides a prospective for the future which includes recently characterized and emerging biomarkers. Written by experts in the field, Molecular Testing in Cancer serves as a useful and comprehensive resource for pathologists, hematologists, laboratory technicians and molecular scientists. |
| colorectal cancer targeted therapy: Multidisciplinary Treatment of Colorectal Cancer Gunnar Baatrup, 2015 This book is intended as the equivalent of the Swiss Army knife for all members of colorectal cancer (CRC) multidisciplinary teams and those training in the fields of CRC management. It describes how to organize the team and explains the basic principles within the different disciplines involved in the treatment and care of CRC patients. Important, up-to-date knowledge is provided on visualization techniques, surgery, oncological treatment, palliation, and pathology, with special focus on controversies and aspects of interest to all team members. Care has been taken to ensure that each specialty-specific chapter will be approachable for team members from other specialties or professions, thereby facilitating an effective interdisciplinary approach to teamwork. The authors include leading European doctors and scientists who have influenced the development of the multidisciplinary team concept as well as other aspects of high-quality, individualized treatment of CRC patients. |
| colorectal cancer targeted therapy: Perioperative Chemotherapy U. Metzger, F. Largiader, H.-J. Senn, 2012-12-06 One reason for failure to cure solid tumors by surgery appears to be the impossibility of controlling metastases that are present but latent at the time of operation. This failure is a common clinical experience with aggressive neoplasms. but it is not always appreciated in tumors with longer survival times. e. g .• breast and colon cancer. In addition. recent evidence indicates that after resection of a primary tumor micrometas tases from it might be enhanced by suppression of immune and reticu loendothelial functions of the host. Other factors, such as increase of coagulability and stress in the perioperative period, can also promote tumor growth. The development of new metastases might be facilitated by cells forced into the circulation during operative manipulations. Such events could be important for the outcome of treatment and it is suggested that preventive measures should be directed to this systemic component of solid tumors. Radical surgery can reduce the number of tumor cells to a subclinical 3 6 stage (10 to 10 cells) in which chemotherapy might be more effective than in advanced stages. Chemotherapy, on the other hand, might aggravate the surgical morbidity by influencing the wound healing pro cess, by decreasing the immune response, and/or by toxicity to the bone marrow and to the gastrointestinal tract, for example. |
| colorectal cancer targeted therapy: Adjuvant Therapy for Breast Cancer Monica Castiglione, Martine J. Piccart, 2009-07-11 Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction of new targeted therapies, metastasizing cancer remains highly incurable. |
| colorectal cancer targeted therapy: Natural Bio-active Compounds Mohd Sayeed Akhtar, Mallappa Kumara Swamy, Uma Rani Sinniah, 2019-09-06 Bioactive compounds produced by natural sources, such as plants, microbes, endophytic fungi, etc., can potentially be applied in various fields, including agriculture, biotechnology and biomedicine. Several bioactive compounds have proved to be invaluable in mediating plant-microbe interactions, and promoting plant growth and development. Due to their numerous health-promoting properties, these compounds have been widely used as a source of medication since ancient times. However, there is an unprecedented need to meet the growing demand for natural bioactive compounds in the flavor and fragrance, food, and pharmaceutical industries. Moreover, discovering new lead molecules from natural sources is essential to overcoming the rising number of new diseases. In this regard, natural bioactive compounds hold tremendous potential for new drug discovery. Therefore, this field of research has become a vital area for researchers interested in understanding the chemistry, biosynthetic mechanisms, and pharmacological activities of these bioactive metabolites. This book describes the basics of bioactive plant compounds, their chemical properties, and their pharmacological biotechnological properties with regard to various human diseases and applications in the drug, cosmetics and herbal industries. It offers a valuable asset for all students, educators, researchers, and healthcare experts involved in agronomy, ecology, crop science, molecular biology, stress physiology, and natural products. |
| colorectal cancer targeted therapy: Successes and Limitations of Targeted Cancer Therapy S. Peters, R.A. Stahel, 2014-02-19 The treatment of patients with advanced malignancies has undergone remarkable change in the last few years. While in the past decisions about systemic therapy were largely based on the performance status of a patient, oncologists today also take into account the pathological and molecular characteristics of the patient’s tumor. Targeting specific molecular pathways important for tumorigenesis has become the preferred way of treatment for many types of malignancies. With these advances come new challenges including the optimization of therapy, recognizing and dealing with side effects and, importantly, the development of resistance. This book provides an up-to-date overview of the advances and limitations of targeted therapy for several tumor entities including breast cancer, colon cancer, gastrointestinal stromal tumors, lung cancer, melanoma, ovarian cancer and renal cell carcinoma. Written by over a dozen internationally renowned scientists, the book is suitable for advanced students, postdoctoral researchers, scientists and clinicians who wish to update their knowledge of the latest approaches to targeted cancer therapies. |
| colorectal cancer targeted therapy: Toxicity of Chemotherapy Michael Clinton Perry, John W. Yarbro, 1984 |
| colorectal cancer targeted therapy: Dermatologic Principles and Practice in Oncology Mario E. Lacouture, 2013-11-26 The first book focusing specifically on frequent and frequently disabling side effects involving the skin, hair and nails in cancer patients According to the World Health Organization, there are approximately thirty million people living with a diagnosis of cancer – the majority of whom will receive surgery, systemic therapy, and/or radiation, and who will suffer from dermatologic adverse events. Dermatologists and oncologists are only beginning to grapple with these events, which pose serious quality-of-life issues with so many patients, and will become more prevalent as survival rates improve, thanks in part to new cancer treatments and drug regimens. Concentrating on a topic that has only been briefly touched upon by other texts, this book offers a focused perspective on the clinical presentation, underlying pathophysiologic mechanisms, and management of skin, hair, and nail conditions for oncologists, dermatologists, and allied practitioners. Dermatologic Principles and Practice in Oncology: Conditions of the Skin, Hair, and Nails in Cancer Patients: • Covers in detail the dermatologic adverse events of oncologic therapies, clinical presentations, and treatment recommendations • Enables dermatologists and other practitioners to significantly improve the care of patients with cancer • Addresses the dermatologic adverse events of cancer therapies used globally, of which a large number are found in developing countries • Emphasizes prophylactic measures – based on treatments used and type of cancer – to prevent the appearance of adverse events • Provides built-in discussions on patient education for practical counseling during therapies • Offers rapid-reference sections on topical dermatology drugs The first book to present dermatologic conditions in cancer patients and survivors in a uniform and in-depth manner, Dermatologic Principles and Practice in Oncology is ideal for oncologists, oncology nurses, and dermatologists who wish to take better care of those with adverse skin, hair, and nail conditions. |
| colorectal cancer targeted therapy: Chinmedomics Xijun Wang, Aihua Zhang, Hui Sun, 2015-07-15 Chinmedomics: The Integration of Serum Pharmacochemistry and Metabolomics to Elucidate the Scientific Value of Traditional Chinese Medicine uses new experimental techniques and research to open doors in drug discovery and development related to traditional Chinese medicine (TCM). This book features a unique approach that combines chemometric analysis with metabolomics studies to illuminate significant changes that have occurred in syndrome states while simultaneously analyzing the efficacy of chemical ingredients in herbal medicines. Chapters provide cutting-edge information on traditional medicine, analytical technology, natural products, metabolomics, bioinformatics and their applications. This book provides a valuable resource for pharmacologists, pharmaceutical scientists, medicinal plant researchers, pharmacognosists and chemists working with TCM and highlights ways to further research and advances in this area in the future. - Presents a practical guide for new practitioners of Chinmedomics with insights on the current use and future development of this method - Each chapter includes an introduction, method, references to the latest literature, possible mechanisms of action and applications - Edited by the leading experts of research related to Chinmedomics |
| colorectal cancer targeted therapy: Targeted Therapies in Cancer Marc Lacroix, 2016 Besides surgery, radiation therapy, endocrine therapy or chemotherapy, which were widely used in cancer patients for decades, the 21st century has seen the emergence of targeted therapy, resulting from the identification of molecular pathways in cells and their alterations in tumors. An increasing number of compounds targeting specific molecules or cancer cells have been developed and, for some of them, approved by the United States Food and Drug Administration (FDA) as well as other regulators in EU and Japan Additional new and more efficient types of compounds, are still in clinical trials, but are expected to gain future approval. More than eighty FDA-approved targeted therapies are described here, along with about eighty other promising compounds. These drugs are members of various therapy classes, including tyrosine kinase inhibitors; serine/threonine kinase inhibitors; dual specificity kinase inhibitors; lipid kinase inhibitors; poly ADP ribose polymerase inhibitors; monoclonal antibodies; microtubule targeting agents; histone deacetylase inhibitors; proteasome inhibitors; antimetabolites; immunomodulatory agents; DNA methyltransferase inhibitors; hedgehog pathway inhibitors; enzymes; protein translation inhibitors; vaccines, oncolytic viruses; chimeric antigen receptor T-cells (CAR-T); and so on. A series of companion diagnostics intended to be used as an indication for specific therapies, and approved to this aim are also mentioned. The book aims to present the broad landscape of compounds and companion diagnostics that are expected to pave the way towards a future of hope for cancer patients. |
| colorectal cancer targeted therapy: Targeted Therapies in Cancer Manfred Dietel, 2014-11-23 From its introduction, oncological chemotherapy has been encumbered by poor selectivity because antiproliferative drugs are often toxic not only to tumor cells but also to important populations of the body’s non-neoplastic cells. Modern targeted therapies interact with defined molecules present on cancer cells, adding increased selectivity to their toxic effects. This book presents an integrated critical view on the theories, mechanisms, problems and pitfalls of the targeted therapy approach. |
| colorectal cancer targeted therapy: Clinical Trials in Oncology, Third Edition Stephanie Green, Jacqueline Benedetti, Angela Smith, John Crowley, 2012-05-09 The third edition of the bestselling Clinical Trials in Oncology provides a concise, nontechnical, and thoroughly up-to-date review of methods and issues related to cancer clinical trials. The authors emphasize the importance of proper study design, analysis, and data management and identify the pitfalls inherent in these processes. In addition, the book has been restructured to have separate chapters and expanded discussions on general clinical trials issues, and issues specific to Phases I, II, and III. New sections cover innovations in Phase I designs, randomized Phase II designs, and overcoming the challenges of array data. Although this book focuses on cancer trials, the same issues and concepts are important in any clinical setting. As always, the authors use clear, lucid prose and a multitude of real-world examples to convey the principles of successful trials without the need for a strong statistics or mathematics background. Armed with Clinical Trials in Oncology, Third Edition, clinicians and statisticians can avoid the many hazards that can jeopardize the success of a trial. |
| colorectal cancer targeted therapy: Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies Chi Hin Cho, Tao Hu, 2020-05-27 Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies, Volume Eight, summarizes the molecular mechanisms of drug resistance in colorectal cancer, along with the most up-to-date therapeutic strategies available. The book discusses reasons why colorectal tumors become refractory during the progression of the disease, but also explains how drug resistance occurs during chemotherapy. In addition, users will find the current therapeutic strategies used by clinicians in their practice in treating colorectal cancer. The combination of conventional anticancer drugs with chemotherapy-sensitizing agents plays a pivotal role in improving the outcome of colorectal cancer patients, in particular those with drug-resistant cancer cells. From a clinical point-of-view, the content of this book provides clinicians with updated therapeutic strategies for a better choice of drugs for drug-resistant colorectal cancer patients. It will be a valuable source for cancer researchers, oncologists and several members of biomedical field who are dedicated to better treat patients with colorectal cancer. |
| colorectal cancer targeted therapy: Tumor Microenvironment and Cellular Stress Constantinos Koumenis, Ester Hammond, Amato Giaccia, 2013-11-23 The collection of chapters in this proceeding volume reflects the latest research presented at the Aegean meeting on Tumor Microenvironment and Cellular Stress held in Crete in Fall of 2012. The book provides critical insight to how the tumor microenvironment affects tumor metabolism, cell stemness, cell viability, genomic instability and more. Additional topics include identifying common pathways that are potential candidates for therapeutic intervention, which will stimulate collaboration between groups that are more focused on elucidation of biochemical aspects of stress biology and groups that study the pathophysiological aspects of stress pathways or engaged in drug discovery. |
| colorectal cancer targeted therapy: Management of Colorectal Cancer Harry Bleiberg, Phillipe Rougier, Hans-Joachim Wilke, 1997-09-17 Focusing on recent developments in the understanding and treatment of colorectal cancer, this detailed reference covers all aspects of the disease, with contributions from a strong international team of authors. * Includes chapters on genetics and molecular pathology * Provides a comprehensive overview of current and developing treatment strategies * Covers preoperative treatment and surgery, chemotherapy, biological therapies, and much more |
| colorectal cancer targeted therapy: Advances in the Molecular Understanding of Colorectal Cancer Eva Segelov, 2019-02-06 An understanding of the molecular pathogenesis of colorectal cancer by researchers and clinicians is essential to facilitate progress in improving patient outcomes in this common cancer that still carries a poor prognosis if not identified early. This book covers the major areas of importance in the field, incorporating new knowledge that has arisen due to the advancement of molecular techniques and the ability to correlate molecular changes with clinical behaviour of tumours. Each chapter is a summary written by experts, concisely summarising current data as well as highlighting potential areas for advancement. Appreciating the differences between tumours on a molecular level is the key to developing and delivering precision medicine, and nowhere is this more critically required than in the field of colorectal cancer. |
| colorectal cancer targeted therapy: Immunotherapy of Hepatocellular Carcinoma Tim F. Greten, 2018-08-22 In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients. |
| colorectal cancer targeted therapy: Antineoplastons Burzynski Research Institute, 1988 |
| colorectal cancer targeted therapy: Targeted Therapies for Solid Tumors Antonio Russo, Rafael Rosell, Christian Rolfo, 2015-03-11 This volume provides readers a comprehensive and state-of-the-art overview about the range of applications of targeted therapies for solid tumors. The sections of the book have been structured to review the oncogene addicted tumors, the pharmacology and clinical development of new molecularly targeted agents, the use of biomarkers as prognostic, predictive and surrogate endpoints, and the evaluation of tumor response and specific malignancies treated with targeted agents. The book also covers some of the newest developments in cancer therapy that are not adequately covered by any current available literature. Written by recognized experts in the field, Targeted Therapies for Solid Tumors: A Handbook for Moving Toward New Frontiers in Cancer Treatment provides a unique and valuable resource in the field of molecular oncology, both for those currently in training, and for those already in clinical or research practice. |
| colorectal cancer targeted therapy: The Cell Cycle and Cancer Renato Baserga, 1971 |
| colorectal cancer targeted therapy: Molecular Mechanisms and Targeted Therapies for Colorectal Cancer Shilpa S. Dhar, Erika Ruiz-Garcia, Valeria Barresi, Oronzo Brunetti, 2022-11-18 |
| colorectal cancer targeted therapy: Genetics of Colorectal Cancer John D. Potter, Noralane M. Lindor, 2008-12-08 Genetic susceptibility refers to how variations in a person’s genes increase or decrease his or her susceptibility to environmental factors, such as chemicals, radiation and lifestyle (diet and smoking). This volume will explore the latest findings in the area of genetic susceptibility to gastrointestinal cancers, focusing on molecular epidemiology, DNA repair, and gene-environment interactions to identify factors that affect the incidence of GI cancers. Topics will include germline susceptibility, including Mendelian patterns of inheritance and gene-environment interactions that lead to cancer etiology. |
| colorectal cancer targeted therapy: Molecular Pathogenesis of Colorectal Cancer Kevin M. Haigis, Ph.D., 2013-10-02 Colorectal cancer has for more than two decades served as the paradigm for the multi-step concept of cancer initiation and progression. Perhaps more than any other organ site, cancer of the colon is extensively characterized at the molecular level. We are now entering a time when molecular classification, rather than histologic classification, of cancer subtypes is driving the development of clinical trials with emerging targeted therapies. The book will focus on the progression from the identification of mutations that drive colorectal cancer initiation and progression to the search for novel therapies to treat the disease. |
| colorectal cancer targeted therapy: The Gerson Therapy Charlotte Gerson, Morton Walker, 2001 Offers a nutritional program that utilizes the healing powers of organic fruits and vegetables to reverse the effects of cancer and other illnesses. |
| colorectal cancer targeted therapy: Colon Cancer Diagnosis and Therapy Vol. 3 Dhananjay Shukla, Naveen Kumar Vishvakarma, Ganji Purnachandra Nagaraju, 2022-02-14 Colorectal cancer (CRC) is a major global health challenge as the third leading cause for cancer related mortalities worldwide. Despite advances in therapeutic strategies, the five-year survival rate for CRC patients has remained the same over time due to the fact that patients are often diagnosed in advanced metastatic stages. Drug resistance is another common reason for poor prognosis. Researchers are now developing advanced therapeutic strategies such as immunotherapy, targeted therapy, and combination nanotechnology for drug delivery. In addition, the identification of new biomarkers will potentiate early stage diagnosis. This book is the third of three volumes on recent developments in colorectal diagnosis and therapy. Each volume can be read on its own, or together. Each volume focuses on different novel therapeutic advances, biomarkers, and identifies therapeutic targets for treatment. Written by leading international experts in the field, coverage addresses the role of diet habits and lifestyle in reducing gastrointestinal disorders and incidence of CRC. Chapters discuss current and future diagnostic and therapeutic options for colorectal cancer patients, focusing on immunotherapeutics, nanomedicine, biomarkers, and dietary factors for the effective management of colon cancer. |
| colorectal cancer targeted therapy: Targeted Therapies in Cancer Manfred Dietel, 2007-06-10 From its introduction, oncological chemotherapy has been encumbered by poor selectivity because antiproliferative drugs are often toxic not only to tumor cells but also to important populations of the body’s non-neoplastic cells. Modern targeted therapies interact with defined molecules present on cancer cells, adding increased selectivity to their toxic effects. This book presents an integrated critical view on the theories, mechanisms, problems and pitfalls of the targeted therapy approach. |
Colon and Rectal Surgery | MedStar Health
MedStar Health's physicians are specifically trained in the latest techniques for the diagnosis and treatment of diseases of the colon and rectum. We offer symptomatic relief and treatment for …
What Is Colorectal Cancer? | How Does Colorectal Cancer Start?
Colorectal cancer is a cancer that starts in the colon or the rectum. Learn about the types of colorectal cancer, how they start, and where they grow.
Colon cancer - Symptoms and causes - Mayo Clinic
Dec 19, 2024 · Colon cancer is sometimes called colorectal cancer. This term combines colon cancer and rectal cancer, which begins in the rectum. Many people with colon cancer don't …
Colorectal Oncology, Colon, or Rectum Oncology Center: …
Colorectal cancer, sometimes called colon cancer, starts when cells that line your colon or rectum grow out of control. In its early stages, colorectal cancer may not have symptoms. Problems...
What is Colorectal Cancer? Symptoms, Risk Factors & Treatments …
Colorectal cancer is a cancer that begins in the colon or rectum. Colorectal cancers are the third most common type of cancer in the United States. More than 145,000 people in this country …
Colon Cancer: Symptoms, Stages, Outlook, and More - Healthline
Feb 28, 2025 · Colon cancer is a type of cancer that starts in your colon (large intestine). It’s often referred to as colorectal cancer. However, colorectal cancer is a group of cancers that includes …
Colorectal Cancer | UM Greenebaum Comprehensive Cancer Center
Large bowel (colon) resection is recommended for a variety of diseases and conditions, including: Why Have This Procedure at the UM Medical Center? Surgeons at the University of Maryland …
Colorectal Cancer | Colorectal Cancer | CDC
Learn about symptoms, risk factors, screening, and treatment. The best way to lower your risk is to get screened regularly. The latest federal data on colorectal cancer cases and deaths. Be …
Colorectal Cancer—Patient Version - NCI
Colorectal cancer often begins as a growth called a polyp inside the colon or rectum. Finding and removing polyps can prevent colorectal cancer. Explore the links on this page to learn more …
Colorectal Cancer | Colon Cancer | Rectal Cancer | MedlinePlus
Mar 5, 2024 · Colorectal cancer starts in the colon or rectum. It may not cause symptoms at first. Screening tests can help find it early, when treatment is most effective.
Colon and Rectal Surgery | MedStar Health
MedStar Health's physicians are specifically trained in the latest techniques for the diagnosis and treatment of diseases of the colon and rectum. We offer symptomatic relief and treatment for …
What Is Colorectal Cancer? | How Does Colorectal Cancer Start?
Colorectal cancer is a cancer that starts in the colon or the rectum. Learn about the types of colorectal cancer, how they start, and where they grow.
Colon cancer - Symptoms and causes - Mayo Clinic
Dec 19, 2024 · Colon cancer is sometimes called colorectal cancer. This term combines colon cancer and rectal cancer, which begins in the rectum. Many people with colon cancer don't …
Colorectal Oncology, Colon, or Rectum Oncology Center: …
Colorectal cancer, sometimes called colon cancer, starts when cells that line your colon or rectum grow out of control. In its early stages, colorectal cancer may not have symptoms. Problems...
What is Colorectal Cancer? Symptoms, Risk Factors
Colorectal cancer is a cancer that begins in the colon or rectum. Colorectal cancers are the third most common type of cancer in the United States. More than 145,000 people in this country …
Colon Cancer: Symptoms, Stages, Outlook, and More - Healthline
Feb 28, 2025 · Colon cancer is a type of cancer that starts in your colon (large intestine). It’s often referred to as colorectal cancer. However, colorectal cancer is a group of cancers that includes …
Colorectal Cancer | UM Greenebaum Comprehensive Cancer …
Large bowel (colon) resection is recommended for a variety of diseases and conditions, including: Why Have This Procedure at the UM Medical Center? Surgeons at the University of Maryland …
Colorectal Cancer | Colorectal Cancer | CDC
Learn about symptoms, risk factors, screening, and treatment. The best way to lower your risk is to get screened regularly. The latest federal data on colorectal cancer cases and deaths. Be …
Colorectal Cancer—Patient Version - NCI
Colorectal cancer often begins as a growth called a polyp inside the colon or rectum. Finding and removing polyps can prevent colorectal cancer. Explore the links on this page to learn more …
Colorectal Cancer | Colon Cancer | Rectal Cancer | MedlinePlus
Mar 5, 2024 · Colorectal cancer starts in the colon or rectum. It may not cause symptoms at first. Screening tests can help find it early, when treatment is most effective.
